JP2024536491A5 - - Google Patents
Info
- Publication number
- JP2024536491A5 JP2024536491A5 JP2024522207A JP2024522207A JP2024536491A5 JP 2024536491 A5 JP2024536491 A5 JP 2024536491A5 JP 2024522207 A JP2024522207 A JP 2024522207A JP 2024522207 A JP2024522207 A JP 2024522207A JP 2024536491 A5 JP2024536491 A5 JP 2024536491A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163255597P | 2021-10-14 | 2021-10-14 | |
| US63/255,597 | 2021-10-14 | ||
| US202263328008P | 2022-04-06 | 2022-04-06 | |
| US63/328,008 | 2022-04-06 | ||
| PCT/US2022/078037 WO2023064850A1 (en) | 2021-10-14 | 2022-10-13 | Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (erap1) inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024536491A JP2024536491A (ja) | 2024-10-04 |
| JPWO2023064850A5 JPWO2023064850A5 (https=) | 2025-09-05 |
| JP2024536491A5 true JP2024536491A5 (https=) | 2025-09-05 |
Family
ID=84332068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024522207A Pending JP2024536491A (ja) | 2021-10-14 | 2022-10-13 | 小胞体アミノペプチダーゼ１（ｅｒａｐ１）阻害剤によるぶどう膜炎の治療 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US12157891B2 (https=) |
| EP (1) | EP4416286A1 (https=) |
| JP (1) | JP2024536491A (https=) |
| MX (1) | MX2024004558A (https=) |
| WO (1) | WO2023064850A1 (https=) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8968731B2 (en) * | 2009-10-09 | 2015-03-03 | Csl Limited | Treatment of uveitis |
| US20130315933A1 (en) * | 2010-10-06 | 2013-11-28 | Christoph Renner | Antibodies Directed Against HLA-B27 Homodimers and Methods and Uses Thereof in Diagnosis and Therapy |
| TWI619729B (zh) * | 2012-04-02 | 2018-04-01 | 再生元醫藥公司 | 抗－ｈｌａ－ｂ*２７抗體及其用途 |
| WO2014155278A2 (en) * | 2013-03-26 | 2014-10-02 | Novartis Ag | Methods of treating autoimmune diseases using il-17 antagonists |
| EP4058429A1 (en) | 2019-11-14 | 2022-09-21 | Grey Wolf Therapeutics Limited | Erap1 modulators |
| AU2021316196B2 (en) | 2020-07-25 | 2025-09-25 | Regeneron Pharmaceuticals, Inc. | Modulation of endoplasmic reticulum aminopeptidase 2 (ERAP2)-mediated immune response |
-
2022
- 2022-10-13 US US18/046,291 patent/US12157891B2/en active Active
- 2022-10-13 JP JP2024522207A patent/JP2024536491A/ja active Pending
- 2022-10-13 WO PCT/US2022/078037 patent/WO2023064850A1/en not_active Ceased
- 2022-10-13 MX MX2024004558A patent/MX2024004558A/es unknown
- 2022-10-13 EP EP22802441.0A patent/EP4416286A1/en active Pending
-
2024
- 2024-10-24 US US18/925,493 patent/US20250115918A1/en active Pending